Scientists have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH). Research published in Nature Communications shows that treatment with a specific antibody can reverse the process behind the development of PAH, and will now be considered for clinical development.
Pulmonary arterial hypertension or PAH is a rare but fatal disease with the only cure being lung transplantation. It results in high blood within the lungs due to the constriction and overgrowth of the cells within the arteries that supply blood to the lungs.
Over time this growth restricts blood flow through these vessels, putting strain on the heart and eventually causing heart failure.
The study found osteoprotegerin (OPG) - which has primarily been thought to just regulate bone density - drives the process behind the growth of the cells within the blood vessel walls affected in PAH.
A therapeutic human anti-OPG antibody was found to stop the progress of the disease in experimental lab rodent and cell models, and reverse the proliferation of cells which cause the arteries to thicken.
The senior author said: "Current treatments for PAH ease the symptoms by relaxing and dilating the affected blood vessels which can help extend the life expectancy for those living with PAH, but they do not stop the underlying drivers of the disease.
"The great benefit of this research is the potential for this new drug to be used in conjunction with current treatments, to ease symptoms and further halt or reverse the progression of the disease."
PAH is a rare disease, affecting less than 1 in 2000 people and has 'orphan disease' designation, meaning that despite smaller numbers of patients affected there is a recognised need for effective treatments to be developed.
https://www.sheffield.ac.uk/news/nr/new-potential-treatment-for-pulmonary-hypertension-1.872704
https://www.nature.com/articles/s41467-019-13139-9
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fa-therapeutic-antibody&filter=22
A therapeutic antibody to target pulmonary arterial hypertension
- 1,025 views
- Added
Edited
Latest News
Hyperactive platelets from…
By newseditor
Posted 19 May
Chromatin and RNA interacti…
By newseditor
Posted 18 May
Why patients with ARID1A mu…
By newseditor
Posted 18 May
Smuggling small molecule mo…
By newseditor
Posted 18 May
Men with gene mutations are…
By newseditor
Posted 17 May
Other Top Stories
Drumming improves behavior and brain function in autistic adolescents
Read more
How the brain controls symptoms of sickness
Read more
A novel membraneless organelle routes cell debris to proteasome dur…
Read more
A brain circuit for addiction remission
Read more
Estimating tumor-specific total mRNA level predicts cancer outcomes
Read more
Protocols
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Publications
An age-progressive platelet…
By newseditor
Posted 19 May
Immunotherapy for colorecta…
By newseditor
Posted 18 May
Single-cell multiplex chrom…
By newseditor
Posted 18 May
Autophagy preferentially de…
By newseditor
Posted 18 May
Poison Ivy, Poison Oak, and…
By newseditor
Posted 18 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar